A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors (2019) Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, et al. Journal article CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells (2018) Jitschin R, Saul D, Braun M, Tohumeken S, Kischel R, Lutteropp M, Dos Santos C, et al. Journal article Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports (2018) Schliep S, Agaimy A, Kiesewetter F, Schuler G, Heinzerling L, Cavallaro AJ Journal article Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (2016) Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, et al. Journal article